27
https://pubmed.ncbi.nlm.nih.gov/38115002
The abstract suggests that incorporating genotyping data into efficacy estimators may not consistently improve the efficiency of early phase malaria vaccine trials, as the power gain from these methods depends on the context and may not be recommended as primary endpoints for small trials.